T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.

Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.

NICE recommended trastuzumab deruxtecan for reimbursement in England for HER2-low metastatic breast cancer, backed by DESTINY-Breast04 data.

ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases.

Trastuzumab botidotin more than doubled median PFS vs trastuzumab emtansine in HER2-positive advanced breast cancer in the phase 3 KL166-III-06 trial.

Lutetium Lu 177 dotatate injection has been approved by the FDA for patients with somatostatin receptor-positive GEP-NETs.

Camizestrant/palbociclib did not significantly improve PFS vs anastrozole/palbociclib in first-line ER+/HER2– breast cancer in the phase 3 SERENA-4 trial.

Erica L. Mayer, MD, MPH, discussed the practical questions clinicians must answer as the SERENA-6 early-switch approach with camizestrant enters practice.